23
Feb

2017

Prevention, Not Cure, as a Way Forward in Alzheimer’s Disease

Many of us have read with dismay of recent clinical trial failures in Alzheimer’s disease. Are researchers and pharma companies wrong in considering amyloid as a target for therapies? Not necessarily. As a recent cover article in Newsweek points out, the problem with many of these trials may not be the target but the point…more »

24
Jul

2015

Mixed results in Alzheimer’s trials but continued enthusiasm for the amyloid hypothesis and the development of treatments

At the Alzheimer’s Association International Conference (AAIC) this week in Washington DC, Biogen and Eli Lilly presented results from their latest Alzheimer’s disease clinical trials. Biogen caused a great deal of excitement earlier this year when they released data from a Phase 1b clinical trial using an antibody to remove amyloid from the brain (see…more »

23
Mar

2015

Biogen success heralds new enthusiasm for investments in Alzheimer’s disease clinical trials

On March 17, 2015 Biogen reported interim results of its recent clinical trial using an antibody to treat Alzheimer’s disease. These results were extremely encouraging as they demonstrated both significant reductions in amyloid and improvements in cognition in patients with Alzheimer’s disease.  This success is certain to stimulate new enthusiasm for investing in clinical trials…more »

18
Dec

2014

Independent support for the role of microglia in Alzheimer’s disease

I was very excited to read about research recently published by a group from Stanford regarding the potential role for microglia in Alzheimer’s disease (http://med.stanford.edu/news/all-news/2014/12/blocking-receptor-in-brains-immune-cells-counters-alzheimers.html). While the work by Karin Andreasson and her team focuses on a receptor protein called EP2, the underlying conclusions of her research – that restoring the activity of microglia to…more »

18
Sep

2014

Signs of optimism for neurodegeneration research

On Monday, September 8th 2014 I had the pleasure of meeting several GliaCure investors at our annual shareholders’ meeting. In addition to dealing with the normal business of this meeting we were able to update the shareholders on our latest progress and on our timeline for plans for 2015. I am always thrilled by the excitement of…more »

21
Aug

2014

President’s Blog

About once a month, or when there is noteworthy information to pass along, I will write a short piece to update you on my thoughts about glia, GliaCure’s progress or general news in the industry. Today I want to comment on a study performed by a group from the Salk Institute, La Jolla, California. Some…more »